2021
Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
Guha A, Caraballo C, Jain P, Miller PE, Owusu‐Guha J, Clark KAA, Velazquez EJ, Ahmad T, Baldassarre LA, Addison D, Weintraub NL, Desai NR. Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure 2021, 8: 2866-2875. PMID: 33982867, PMCID: PMC8318466, DOI: 10.1002/ehf2.13362.Peer-Reviewed Original ResearchConceptsAnthracycline-induced cardiomyopathyIschemic cardiomyopathyCardiomyopathy patientsCF-LVADICM patientsLeft ventricular assist device implantationContinuous-flow LVAD implantationHigher major bleeding riskVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportCox proportional hazards modelCF-LVAD implantationAcute kidney injuryMajor bleeding riskAssist device implantationEtiology of cardiomyopathyProportional hazards modelBleeding riskKidney injuryInteragency RegistryLVAD implantationMajor infectionMedian survivalRespiratory supportEffect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure
Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.Peer-Reviewed Original ResearchConceptsEnd-stage heart failureReduced ejection fractionHealth-related qualityPatient-reported health statusEffect of inotropesHeart failureHealth status domainsEjection fractionHealth statusFunctional statusPositive inotropesStatus domainsAvailable clinical trial dataMorbidity/mortalityPopulation of patientsPatient-centered outcomesHealth status outcomesClinical trial dataFunctional capacity changesQuantity of lifeWeb of ScienceInotrope therapyInotrope useCalcium sensitizerSurvival benefit
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomes
2019
Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients
Stawiarski K, Agboola O, Jacoby D, Bellumkonda L, Ahmad T, Sugeng L, Chen M, McCloskey G, Geirsson A, Anwar M, Bonde P. Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients. The Journal Of Heart And Lung Transplantation 2019, 38: s382-s383. DOI: 10.1016/j.healun.2019.01.974.Peer-Reviewed Original ResearchSerum chloride levelsChloride homeostasisLVAD patientsHeart failureLVAD therapyEnd-stage heart failureCardio-renal axisChronic heart failureStage heart failureChloride levelsLong-term survivalKaplan-Meir plotsLog-rank statisticsL riseCause mortalityLVAD recipientsWorse survivalSingle centerNeurohormonal responsesPrognostic implicationsPrognostic valueLVAD implantsRetrospective analysisGroup ACox model